List of Diagnostics Companies in Netherlands - 14

ANT Neuro is a Dutch corporation specialized in the development, marketing and sales of medical and research applications. ANT Neuro was established in 1997 as a spin-off company of The University of Twente, Enschede. It now has offices located in Hengelo, Netherlands; Berlin, Germany; London, UK; Philadelphia, USA; Melbourne, Australia; and Hong Kong, China. ANT Neuro specializes in being a single-source provider of high performance products within neuroscience research and neurodiagnostics. Applications include EEG, EMG, TMS and MEG technology.

GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. We combine our renowned software and reagents for high resolution HLA typing by Next Generation Sequencing and Chimerism monitoring, with ex-cellent customer support and education. We work closely with our partners and clients and share knowledge to advance the field of trans-plant typing and monitoring. With a highly educated and motivated team of about 90 people and 40 distributors, we contribute to the quality of life of transplant patients worldwide.

By combining machine learning with advanced chemistry, inBiome enables microbiology labs over the world to rapidly and easily identify bacteria in a wide range of clinical sample types, including complex microbiota. Even uncultivable- and antibiotics treated species are detected. Current applications include replacing traditional culture in ICU’s for more accurate, same day results, infection control, gut flora analysis and various r&d applications for healthcare, pharmacy and food industies. Promising new applications currently undergoing clinical trials include IBD and Sepsis dagnostics and preventive screening.

Innatoss Laboratories is a Dutch research intensive organization developing and performing in vitro diagnostics of infectious diseases such as Lyme disease, Q fever and recently COVID-19. With our lab facility located in the center of the largest Q fever epidemic worldwide, we are very aware of our goal: improve diagnostics to detect these infectious diseases as early as possible and rid the world of associated health problems, such as the chronic types of these diseases. Our passion, knowledge and drive will helps us to reach our goals and to assist those who are in need of innovative diagnostics and blood testing services. Recent assignments and achievements include CE certification of the first cell-mediated immunity test for Q fever (Q-detect), consortium membership of a Q fever vaccine development program led by Massachusetts General Hospital and an EU Horizon 2020 grant for the development of a cellular Lyme diagnostic test. We are open to new opportunities, collaborations and existing developments to bring diagnostic tests for infectious diseases to the next level.

InnoSIGN commercializes OncoSIGNal mRNA-based tests that measure the activity of signal transduction pathways in cancer and immune cells to predict how patients will respond to targeted drugs.

Jeta's mission is to improve outcomes for transplant patients by providing the highest quality medical devices available. These tests will provide best in class solutions for post-transplant surveillance of disease relapse, as well as organ and stem cell transplant rejection. Jeta's systems will enable new applications, lead to improved laboratory workflows, lower per test costs and will ideally translate into better patient care and survival rates

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology). We have established deep roots throughout Europe, and more recently, expanded outside of Europe, with the creation of an affiliate in Canada. Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care. Nordic Pharma's values of Commitment, Ambition, Respect, Reliability, Integrity and Agility describe our culture and standards and guide us in our way of working.

By applying nanotechnology, photonics and machine learning, Nostics brings a new type of diagnostics to a world desperately in need for 21st century solutions. We believe that a good life starts with good health. We believe that accessible and affordable diagnostics should be a given for our entire human family. Improvements in healthcare can only start when we know what’s going on. By providing instant and affordable testing at any location, Nostics wants to contribute to a better safer and healthier world.

Scinvivo enables optical biopsy for bladder cancer diagnostics. Current imaging techniques for bladder cancer have their limitations, as they only enable the urologist to visualise the bladder wall surface. In 30% of the cases, healthy tissue is incorrectly classified as cancerous. Another limitation is that it is difficult to fully remove a tumor during a surgical procedure, as the borders of the tumor are difficult to visualize. The last limitation is that it is impossible to determine the invasion depth of the tumor with current imaging technologies, while the invasion depth has major impact on the proposed treatment. All these limitation lead to unnecessary, invasive, and costly interventions. Scinvivos technology enables the urologist to improve diagnosis, and thus decreasing the amount of interventions, patient burden, and costs.

Develops the scopeDx ® platform, a technology that uses proprietary Type III CRISPR-Cas nucleases to detect nucleic acid sequences

The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company's main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types. HPV-Risk Assay The HPV-Risk Assay is an in vitro real-time PCR-based assay The HPV-Risk Assay is an in vitro real-time PCR-based assay for the qualitative detection of human papillomavirus (HPV) DNA, targeting the E7 region of the following 15 (probably) high-risk HPV genotypes, i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67, and 68. The QIAsure Methylation Test The QIAsure Methylation Test is a real-time PCR-based molecular assay The QIAsure Methylation Test is a real-time PCR-based molecular assay to distinguish women with cervical (pre)cancer. The QIAsure Methylation Test specifically detects women with a cancer-like methylation profile that have a short term high risk for progression to cervical cancer.

Develop diagnostic tools for screening of diseases through exhaled breath.

Thirona is a global company based in Nijmegen, the Netherlands, that specializes in AI-powered medical image analysis, focusing on lung and retina images. Founded in 2014, Thirona combines medical science with artificial intelligence to deliver advanced solutions for clinical trials, treatment development, and personalized patient care. The company offers high-precision quantitative analysis of medical images, including lung quantification software that analyzes chest CT scans for lung disease detection and treatment planning. Their services also include the quantification of anatomical volumes, mapping of parenchymal disease distributions, and analysis of airway and vascular morphology. In addition to lung analysis, Thirona provides retina image analysis solutions, such as iCare RETCAD, which detects conditions like diabetic retinopathy and glaucoma. Thirona collaborates with clinical research organizations, multinational MedTech companies, and professionals in interventional pulmonology, supporting over 600 clinical sites in more than 40 countries and contributing to over 200 scientific papers.

ViroNovative BV, established in 2002, is dedicated to providing a complete solution to human Metapneumovirus (hMPV), a virus discovered in 2001 at the Department of Viroscience, Erasmus MC. To this end, ViroNovative is co-developing diagnostics, vaccines, antibodies and antivirals for the detection, prevention and treatment of hMPV infection. With a strong network of industrial partners (to date 20 licenses on the hMPV patents are active) we generate new products and economic value.